Treatment
Treatment 25/09/2008
Switching after treatment failure
Drug resistance, CD4 response, and progression to AIDS and death in patients who delay switching compared with those who switch rapidly after treatment failure.
Treatment 25/09/2008
Ezetimibe safe and effective for cholesterol reduction in patients taking HIV treatment
Ezetimibe can reduce cholesterol and it is often prescribed along with diet modification or statins to patients with high blood lipids.
Treatment 24/09/2008
More evidence that antiretrovirals reduce the risk of non-HIV illnesses at lower CD4 cell counts
HAART use is associated with a decreased risk of comorbidities not related to HIV infection…amongst patients with CD4 cell counts below 350 cells/mm3.
Treatment 23/09/2008
CD4 tests can reduce costs, extend lives of HIV-positive people in Africa, study says
Patients who received the CD4 test alone lived about 11.8 months longer than those whose symptoms were monitored, while those who received viral load testing lived about two months longer.
Treatment 23/09/2008
Contemporary once-daily fixed-dose antiretroviral regimens are more durable than earlier treatment options for HIV patients
The more convenient once-daily fixed-dosed drug regimens and improved drug tolerability of contemporary regimens has allowed for significant gains in initial regimen durability.
Treatment 22/09/2008
Retrovir label update
Retrovir syrup, capsules and tablets label update for twice daily dosing in children 6 weeks to 18 years of age.
Treatment 18/09/2008
Myriad Genetics announces topline results of Phase 1 trial of Vivecon for HIV
Trial indicates favorable safety and pharmacokinetics profiles.
Treatment 18/09/2008
Chamomile may help prevent diabetes and its complications
Daily consumption of chamomile tea with meals could be potentially useful in the prevention and self-medication of hyperglycemia and diabetic complications.
Treatment 18/09/2008
Birth defect screening just as reliable in positive pregnant women
Screening for fetal abnormalities is accurate for pregnant women living with HIV and should be offered, similar to recommendations for HIV-negative women.
Treatment 18/09/2008
HIV progression slower in women than men in HAART era
In settings with small gaps in gender inequality and universal access to care, in the era of HAART, it certainly appears that HIV-infected women fare better than their male counterparts.
Treatment 18/09/2008
Patients staying on first-line HIV treatment combinations for longer
Ease of dosing and improved tolerability were identified by the researchers as the main reasons why patients were able to remain on their treatment for longer.
Treatment 18/09/2008
African study looks at safety of antiretroviral therapy during pregnancy
Combination antiretroviral therapy significantly reduces the risks of women with advanced HIV disease having an HIV-infected baby, but increases the risk of having a low birth weight baby.
Treatment 12/09/2008
Effect of lopinavir/ritonavir monotherapy on symptoms and quality of life
Other therapeutic strategies could be beneficial given the long-term toxicities and quality of life issues associated with taking multiple ARV drugs for many years. One such approach is monotherapy using only a ritonavir-boosted PI.
Treatment 12/09/2008
Time to virological failure with boosted atazanavir or lopinavir/ritonavir is not affected by use of H2 receptor blockers
The findings led the investigators to conclude that the time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2 receptor blockers, was not significantly different.
Treatment 12/09/2008
Cidofovir of no benefit for HIV-related PML
The investigators compared treatment outcomes in HIV-positive patients with PML who were treated with antiretroviral therapy plus cidofovir and patients with the infection who received antiretroviral therapy by itself. They found that mortality and disability were comparable in the two treatment groups.
Treatment 10/09/2008
Study shows patients in their 30s at time of HIV infection have best response to HIV therapy
Patients who are aged in their 30s at the time of infection with HIV have a better response to HIV treatment than individuals aged between 18 – 29.
Treatment 09/09/2008
Recommendations for treatment-experienced HIV patients on failing regimens containing boosted darunavir
There are limited data on resistance patterns that emerge in patients failing darunavir/ritonavir and their effect on subsequent remaining PI treatment options.
Treatment 09/09/2008
Management of elevated blood lipids may be less successful in HIV patients with high cardiovascular risk
These findings highlight the challenge clinicians and patients face modifying major cardiovascular disease risk factors in the HIV-infected population.
Treatment 08/09/2008
PAD common in HIV-positive patients over 50
Left untreated, PAD can cause claudication—cramping, fatigue and discomfort in the legs—and potentially serious kidney damage.
Treatment 05/09/2008
Genes, not race, should guide antiretroviral treatment
A person’s genetic sequence, and not his or her race, should guide scientists and health care providers in the design of clinical trials and treatment decisions with ARV drugs such as efavirenz.
More...
